Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years or older~2. 1 to 3 vertebral compression fracture(s), between T5-L5, responding to the following criteria:~   * at least 15% loss of vertebral body height (anterior, median or posterior);~  * malignant origin (bone metastases, multiple myeloma, hemopathy) assessed by imaging, including an MRI and a CT-SCAN of less than 4 weeks.~  * Pain or painful deterioration less than 3 months old, related to one or more vertebral fractures with a VAS higher than 50/100 mm when changing position, or higher than 40/100 mm if associated with morphine ≥ 30 mg/day ;~3. The pain related to the fractured vertebrae is the more prevalent~4. More than 3 months life expectancy.~5. Blood Platelets rate more than or equal to 50 000/mm3 within the week before balloon kyphoplasty procedure (after a correct blood transfusion).~6. Patient must have signed a consent form.~7. Patient affiliated to social security~Exclusion Criteria:~1. Patient younger than 18~2. Impossibility to perform Balloon Kyphoplasty:~   * Technical impossibility to achieve the percutaneous approach to the vertebra to treat.~  * Vertebral pedicle diameter or height of treated vertebra(e) not sufficient regarding balloon kyphoplasty TROCATHETER size. This should be assessed through prescreening MRI and/or CT-Scan~3. More than three symptomatic vertebral compression fractures in the same vertebral segment.~4. Patient receiving additional local treatment within 15 days after balloon kyphoplasty procedure (surgery, radiofrequency, radiotherapy).~5. Patient with primary bone tumors (eg : osteosarcoma) or single solitary plasmocytoma (patients presenting those tumors on other parts of the body, other than VCF are eligible).~6. Patients presenting sclerotic or mixed vertebral lesions(sclerotic vertebral lesions at another vertebral level are not a contraindication).~7. Patients with less than 3 month life expectancy~8. Patient undergoing an experimental anti-cancerous treatment in Phase I evaluated at the same time~9. Patient having relevant co-morbidities which may interfere with the data management on pain and quality of life.~10. Patient presenting an inadequate vertebra with Balloon Kyphoplasty.~11. Patient undergoing an additional treatment other than balloon kyphoplasty for their vertebral fracture.~12. Patient presenting neurological signs or spinal cord compression or spinal canal narrowing requiring surgical decompression;~13. Patient with a medical or surgical condition not compatible with balloon kyphoplasty procedure (eg : a non-treated local infection)~14. Patient having an allergy to the bone cement and/or to the contrast media used during the balloon kyphoplasty procedure.~15. Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): balloon Kyphoplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility